Editorial Comment.

for primary tumor staging, was similar across ccRCC and nonccRCC histologies, indicating a lack of confounding by tumor stage. Because the E2805 study included a relatively high risk cohort of completely resected RCC cases, these findings may not be generalizable to resected nonccRCC cases with lower estimated recurrence rates. Finally, although no differences were found according to the assigned adjuvant therapy or placebo, it is possible that this analysis had limited power to detect differences in relapse pattern by treatment group. However, consistent findings in analyses restricted to placebo treated patients further strengthen the observed differences in relapse pattern. Further, recently reported findings in similar adjuvant antiangiogenic therapy studies also indicated a lack of effect of adjuvant therapy on observed relapse patterns.